GlassScriptPhysician profile
Alan Huy Tieu
NPI 1427324458
$5,675.60
in general payments reported to CMS, 2019-2025
40 companies · $1,712 in 2025
The $1,712 reported for 2025 was more than what 75% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $553 · 2020: $167 · 2021: $96.93 · 2022: $500 · 2023: $1,090 · 2024: $1,557 · 2025: $1,712.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,312 · Education: $47.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,312.10 |
| Education | $47.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,353.53 | 2019-2025 | Rinvoq, Skyrizi, Mavyret |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $521.81 | 2019-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $494.39 | 2019-2025 | Entyvio, Gattex |
| Janssen Biotech, INC. | $439.11 | 2019-2025 | Stelara, Tremfya, Simponi |
| Gilead Sciences, INC. | $364.70 | 2020-2025 | |
| Regeneron Healthcare Solutions, INC. | $271.54 | 2022-2025 | Dupixent |
| Janssen Scientific Affairs, LLC | $238.89 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $233.61 | 2024-2025 | Iqirvo |
| Ardelyx, INC. | $230.50 | 2023-2025 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $147.17 | 2023-2025 | Linzess |
| E.R. Squibb & Sons, L.L.C. | $124.93 | 2022 | |
| Ferring Pharmaceuticals INC. | $112.80 | 2019-2025 | Rebyota |
| Braintree Laboratories, INC. | $103.90 | 2020-2025 | Suflave, Sutab |
| Daiichi Sankyo INC. | $90.84 | 2020-2025 | Injectafer |
| Celltrion USA INC. | $89.50 | 2024-2025 | Zymfentra, Vegzelma |
Show all 39 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Tieu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.